Myeloperoxidase and free iron levels: potential biomarkers for early
detection and prognosis of ovarian cancer.
Cancer Biomark. 2011-2012;10(6):267-75.
Fletcher NM, Jiang Z, Ali-Fehmi R, Levin NK, Belotte J, Tainsky MA,
Diamond MP, Abu-Soud HM, Saed GM.
Department of Obstetrics and Gynecology, The C.S. Mott Center for
Human Growth and Development, Wayne State University School of
Medicine, Detroit, MI 48201, USA.

OBJECTIVE: The study sought to identify whether a relationship exists
between serum myeloperoxidase (MPO) and free iron with stages of
ovarian cancer.

METHODS: Serum and tissue samples were collected from women with
stages I through IV ovarian cancer, benign gynecologic conditions,
inflammation, and healthy controls. Myeloperoxidase ELISA and VITROS
Fe Slide assays were used to measure serum and tissue MPO and free
iron levels, respectively. Data were analyzed with a one-way ANOVA
with post-hoc comparisons (p < 0.05 considered significant).

RESULTS: There was a significant increase in the level of free iron in
serum and tissues obtained from stages II-IV as compared to early-
stage (stage I) ovarian cancer. There was an overlap between early-
stage and inflammation serum MPO levels, however serum free iron
levels were significantly higher in early-stage. There was no
significant change in serum free iron levels between non-cancer
groups. In contrast, there was a significant increase in serum free
iron levels in early-stage as compared to non-cancer groups.

CONCLUSIONS: Collectively, these findings clearly indicate a role for
the combination of serum MPO and free iron as biomarkers for early
detection and prognosis of ovarian cancer.


doi: 10.3233/CBM-2012-0255.

Who loves ya.

Jesus Was A Vegetarian!

Man Is A Herbivore!